Recently, immune-checkpoint inhibitors targeting the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1), atezolizumab and nivolumab, have been approved by the Food and Drug Administration (FDA) in patients with advanced bladder cancer [50]. Here, CD274 is linked to urinary bladder cancer.